ALRN News and Press, Aileron Therapeutics Inc. From 09/06/22

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aiv...

Aileron Therapeutics press release ( NASDAQ: ALRN ): Q2 GAAP EPS of -$0.09. Cash, cash equivalents, and investments on June 30, 2022, were $32.4 million. For further details see: Aileron Therapeutics GAAP EPS of -$0.09

Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trial Extended cash runway expected to support operations through end of 1Q 2024 Presented new data at the Society f...

Buying Penny Stocks on August 8th? Here’s What You Need to Know If you’re thinking about investing in penny stocks, now is a good time. The stock market has been on a tear lately despite months of mostly bearish sentiment. Now, while penny stocks have been climbing as ...

Trading Penny Stocks in August? 3 Tips to Use August is already getting off to an interesting start for penny stocks and blue chips. The stock market started off the month on a positive note with a major amount of bullish sentiment. However, as the month has gone on, we’ve seen m...

Nano-cap biotech Aileron Therapeutics ( NASDAQ: ALRN ) dropped nearly 12% on Monday after the company announced protocol modifications to its Phase 1b chemoprotection trial for ALRN-6924 in p53-mutated breast cancer. Grounded on recent ALRN-6924 data, the modifications w...

Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancer Key protocol...

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Exec...

Aileron Therapeutics ( NASDAQ: ALRN ) said it plans to stop further enrollment in a phase 1b study of ALRN-6924 after the drug did not reduce chemo induced toxicities compared to placebo, in patients with lung cancer. The drug, however, helped the patients stay on c...

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endp...